While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

phentermine, sibutramine) with patients who are not meeting their goals through diet and exercise alone. Discuss the modest benefits typically achieved with such drugs (<5 kg loss at 1 year ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Moderate-intensity exercise helps regulate appetite and boosts key weight loss hormones, offering benefits similar to weight ...

A recent survey showed American adults split over the use of weight loss drugs as an obesity treatment. There’s a strong base of support, with about half of the people ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...